Logo

Amgen Signs an Exclusive Multi-Year Research Collaboration and License Agreement with Plexium to Advance Novel Targeted Protein Degradation Therapies

Share this

Amgen Signs an Exclusive Multi-Year Research Collaboration and License Agreement with Plexium to Advance Novel Targeted Protein Degradation Therapies

Shots:

  • Plexium to receive ~$500M in success-based target access, pre-clinical/clinical, regulatory & commercial milestones along with royalty, if all options are exercised. The companies will initially focus on 2 programs for cancer
  • Amgen gets an option to add more programs & holds a commercial license to each program that advances to a predefined preclinical stage of development and will lead the global development and commercialization of the product
  • The collaboration will combine Plexium's targeted protein degradation platform with Amgen's early discovery expertise to develop new therapeutic agents for the treatment of cancer and other serious diseases

Ref: Amgen | Image: Adweek

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions